Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- Conditions
- Hematologic Neoplasms
- Interventions
- Procedure: Allogeneic HSCTProcedure: Total Body Irradiation (TBI)
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 320
- Registration Number
- NCT04959175
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of N9 Chemotherapy in Children With Neuroblastoma
- Conditions
- Pediatric CancerNeuroblastoma
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04947501
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Conditions
- Chronic Myelogenous LeukemiaMixed Phenotype Acute LeukemiaAcute LeukemiaAcute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromesLymphoma
- Interventions
- Radiation: Total-body irradiationProcedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)Procedure: Bone Marrow Hematopoietic Stem Cell TransplantationOther: Patient-Reported Outcomes
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 300
- Registration Number
- NCT04904588
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- Conditions
- OsteosarcomaNeuroblastomaDesmoplastic Small Round Cell TumorMalignant Peripheral Nerve Sheath TumorsSoft Tissue SarcomaMelanomaEwing SarcomaAdrenocortical CancerRhabdoid TumorPediatric Solid Tumor
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04897321
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
- Conditions
- Acute Lymphoblastic Leukemia, in RelapsePediatric ALLAcute Lymphoblastic Leukemia, Refractory
- Interventions
- Biological: CD19-CAR(Mem) T-cellsDevice: CliniMACSProcedure: Leukapheresis
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04881240
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- Drug: DS-1594bBiological: FilgrastimBiological: Rituximab
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- Conditions
- Embryonal CarcinomaMalignant TeratomaChoriocarcinomaMixed Germ Cell TumorPineal Region Germ Cell TumorCentral Nervous System Nongerminomatous Germ Cell TumorImmature TeratomaSuprasellar Germ Cell TumorPineal Region Immature TeratomaPineal Region Yolk Sac Tumor
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Peripheral Blood Stem Cell TransplantationOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Second-Look Surgery
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT04684368
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Blank Children's Hospital, Des Moines, Iowa, United States
IS-free Treg HaploHCT
- Conditions
- Stem Cell Transplant ComplicationsGraft Vs Host DiseaseMyeloid Leukemia, AcuteMyeloid Leukemia in Relapse (Disorder)Myelodysplastic Syndromes
- Interventions
- Radiation: RadiationBiological: Treg-enriched donor cellBiological: Unmodified donor T CellProcedure: CD34+ Haplo Peripheral Blood Stem Cell
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04678401
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
- Conditions
- Refractory B Cell Acute Lymphoblastic Leukemia (ALL)Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Biological: CD19 CAR engineered autologous T-cells
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 22
- Registration Number
- NCT04653493
- Locations
- 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Haploidentical HCT for Severe Aplastic Anemia
- Conditions
- Aplastic AnemiaBone Marrow Failure Syndrome
- Interventions
- Radiation: Total Lymphoid Irradiation (TLI)Device: CliniMACSBiological: HPC, A InfusionBiological: CD45RA-depleted DLI
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04558736
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.